Maor Y, Malnick S
Department of Gastroenterology and Hepatology, Sheba Medical Center, 52621 Tel-Hashomer, Israel.
Int J Hepatol. 2013;2013:815105. doi: 10.1155/2013/815105. Epub 2013 Jul 17.
Cytotoxic chemotherapy prolongs survival of patients with advanced and metastatic tumors. This is, however, a double-edged sword with many adverse effects. Since the liver has a rich blood supply and plays an active role in the metabolism of medications, it is not surprising that there can be hepatic injury related to chemotherapy. In addition, radioembolization may affect the parenchyma of normal and cirrhotic livers. We review chemotherapy-associated liver injury in patients with colorectal liver metastases, including downsizing chemotherapy and neoadjuvant chemotherapy. We discuss the mechanism of the hepatic injury, secondary to reactive oxygen species, and the spectrum of hepatic injury including, steatosis, steatohepatitis, hepatic sinusoidal injury and highlight the pharmacogenomics of such liver insults. Methods for reducing and treating the hepatotoxicity are discussed for specific agents including tamxifen and the newly introduced targeted antibodies.
细胞毒性化疗可延长晚期和转移性肿瘤患者的生存期。然而,这是一把双刃剑,存在许多不良反应。由于肝脏血供丰富且在药物代谢中起积极作用,化疗相关的肝损伤也就不足为奇了。此外,放射性栓塞可能会影响正常肝脏和肝硬化肝脏的实质。我们回顾了结直肠癌肝转移患者化疗相关的肝损伤,包括降期化疗和新辅助化疗。我们讨论了继发于活性氧的肝损伤机制,以及肝损伤的范围,包括脂肪变性、脂肪性肝炎、肝窦损伤,并强调了此类肝损伤的药物基因组学。还讨论了针对他莫昔芬和新引入的靶向抗体等特定药物降低和治疗肝毒性的方法。